Skip to main navigation Skip to search Skip to main content

Telemedicine with special focus on allergic diseases and asthma—Status 2022: An EAACI position paper

  • Sylwia Smolinska*
  • , Florin Dan Popescu
  • , Elena Izquierdo
  • , Darío Antolín-Amérigo
  • , Oliver J. Price
  • , Alberto Alvarez-Perea
  • , Ibon Eguíluz Gracia
  • , Nikolaos G. Papadopoulos
  • , Oliver Pfaar
  • , Filippo Fassio
  • , Karin Hoffmann-Sommergruber
  • , Stephanie Dramburg
  • , Ioana Agache
  • , Marek Jutel
  • , Helen A. Brough
  • , João A. Fonseca
  • , Elizabeth Angier
  • , Cristina Boccabella
  • , Matteo Bonini
  • , Audrey Dunn Galvin
  • Peter G. Gibson, Radoslaw Gawlik, Farah Hannachi, Ömer Kalayci, Ludger Klimek, Rebecca Knibb, Paolo Matricardi, Tomás Chivato
*Corresponding author for this work
  • Wrocław Medical University
  • Carol Davila University of Medicine and Pharmacy
  • University CEU San Pablo
  • Hospital Universitario Ramón y Cajal
  • University of Leeds
  • Hospital General Universitario Gregorio Marañón
  • Gregorio Marañón Health Research Institute
  • Instituto de Investigacion Biomedica de Malaga (IBIMA-Plataforma BIONAND). RICORS “Inflammatory Diseases”
  • University of Athens
  • University Hospital Marburg
  • Centro Studi Allergie ETS
  • Medical University of Vienna
  • Charite - Universitatsmedizin Berlin
  • Transylvania University Brasov
  • “ALL-MED” Medical Research Institute
  • Evelina London Children's Healthcare
  • King's College London
  • Faculty of Medicine of the University of Porto
  • University of Southampton, Faculty of Medicine
  • Università Cattolica del Sacro Cuore
  • Università Cattolica del Sacro Cuore
  • National Heart and Lung Institute
  • University College Cork
  • University of Newcastle, Australia
  • Medical University of Silesia
  • Hospital Centre of Luxembourg
  • Hacettepe Üniversitesi
  • Center for Rhinology and Allergology

Research output: Contribution to journalArticlepeer-review

17   Link opens in a new tab Citations (SciVal)

Abstract

Efficacious, effective and efficient communication between healthcare professionals (HCP) and patients is essential to achieve a successful therapeutic alliance. Telemedicine (TM) has been used for decades but during the COVID-19 pandemic its use has become widespread. This position paper aims to describe the terminology and most important forms of TM among HCP and patients and review the existing studies on the uses of TM for asthma and allergy. Besides, the advantages and risks of TM are discussed, concluding that TM application reduces costs and time for both, HCP and patients, but cannot completely replace face-to-face visits for physical examinations and certain tests that are critical in asthma and allergy. From an ethical point of view, it is important to identify those involved in the TM process, ensure confidentiality and use communication channels that fully guarantee the security of the information. Unmet needs and directions for the future regarding implementation, data protection, privacy regulations, methodology and efficacy are described.

Original languageEnglish
JournalAllergy: European Journal of Allergy and Clinical Immunology
Early online date1 Dec 2023
DOIs
Publication statusE-pub ahead of print - 1 Dec 2023

Funding

The Telemedicine task force group within the Research and Outreach Committee (ROC) was supported by the European Academy of Allergy and Clinical Immunology (EAACI).

Funders
European Academy of Allergy and Clinical Immunology

    Keywords

    • e-health
    • m-health
    • telecare
    • telehealth
    • telemedicine

    Fingerprint

    Dive into the research topics of 'Telemedicine with special focus on allergic diseases and asthma—Status 2022: An EAACI position paper'. Together they form a unique fingerprint.

    Cite this